Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01675089|
Recruitment Status : Completed
First Posted : August 29, 2012
Last Update Posted : May 19, 2014
|Condition or disease||Intervention/treatment||Phase|
|Renal Osteodystrophy||Drug: Zoledronic acid||Phase 4|
For the treatment of osteoporosis in the general population, a number of drugs reduce BMD (bone mineral density) loss and the rate of incident fractures. For instance, bisphosphonates improve BMD, reduce hip fracture rates and decrease mortality in post-menopausal women. Because of lack of data on safety and an increased risk of adverse effects, the use of these drugs is controversial in patients with chronic kidney disease (CKD) and abnormalities of PTH or vitamin D, an estimated glomerular filtration rate (GFR) less than 30 ml/min/1.73m² (CKD stages 4 and 5) and after transplantation. The efficacy of short and long term bisphosphonate treatment after kidney transplantation has been examined; however, histomorphometric and fracture rate reduction data are lacking.
The purpose of this study is to determine whether zolendronic acid, a third generation bisphosphonate, is effective in preventing bone loss in the first year after kidney transplantation.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||34 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective and Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year After Kidney Transplantation|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||May 2014|
Experimental: Zoledronic acid
Intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement.
Drug: Zoledronic acid
The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
Other Name: Aclasta
No Intervention: Control
The control group will receive only vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
- Differences in bone turnover [ Time Frame: 1 year ]Bone histomorphometric data will be analyzed at baseline and after 1 year of kidney transplantation.
- Bone microarchitecture [ Time Frame: 1 year ]Bone microarchitecture will be examined by high-resolution peripheral quantitative computed tomography at the time of transplant and after 12 months.
- Changes in Bone Mineral Density [ Time Frame: 1 year ]Bone mineral density (BMD) measurements by dual-energy X-ray absorptiometry (DEXA) will be made at the time of transplant and after 6 and 12 months.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01675089
|Hospital das Clinicas - Faculdade de Medicina da Universidade de São Paulo|
|Sao Paulo, Brazil, 05403-900|
|Principal Investigator:||Elias David-Neto, MD||University of Sao Paulo|